Literature DB >> 7588261

Widespread distribution of somatostatin receptor messenger ribonucleic acids in rat pituitary.

A M O'Carroll1, K Krempels.   

Abstract

The expression of five somatostatin receptor subtypes, rsstr1-5, was examined in rat pituitary by in situ hybridization histochemistry. The anterior lobe of the pituitary expressed mRNA encoding all five rsstr subtypes. Relatively high levels of rsstr3 mRNA expression were also observed in the intermediate lobe of the pituitary. If all five rsstr proteins are expressed in the pituitary, the effects of somatostatin and somatostatin-28 on pituitary function may therefore represent the composite activation of more than one sstr. Co-localization studies on the same pituitary sections revealed a widespread distribution of rsstr mRNA in the major endocrine cell groups. Somatotrophs showed a relatively high level of rsstr4 and -5 mRNA expression while thyrotrophs predominantly expressed rsstr2 mRNA. These data may point to the potential roles for sstr subtypes in mediating SRIF physiology in the pituitary.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7588261     DOI: 10.1210/endo.136.11.7588261

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  10 in total

1.  Multi-responsiveness of single anterior pituitary cells to hypothalamic-releasing hormones: a cellular basis for paradoxical secretion.

Authors:  C Villalobos; L Núñez; L S Frawley; J García-Sancho; A Sánchez
Journal:  Proc Natl Acad Sci U S A       Date:  1997-12-09       Impact factor: 11.205

2.  Somatostatin receptor subtype specificity in human fetal pituitary cultures. Differential role of SSTR2 and SSTR5 for growth hormone, thyroid-stimulating hormone, and prolactin regulation.

Authors:  I Shimon; J E Taylor; J Z Dong; R A Bitonte; S Kim; B Morgan; D H Coy; M D Culler; S Melmed
Journal:  J Clin Invest       Date:  1997-02-15       Impact factor: 14.808

Review 3.  Molecular pharmacology of somatostatin receptor subtypes.

Authors:  Y C Patel
Journal:  J Endocrinol Invest       Date:  1997-06       Impact factor: 4.256

Review 4.  The role of somatostatin analogs in Cushing's disease.

Authors:  Joost van der Hoek; Steven W J Lamberts; Leo J Hofland
Journal:  Pituitary       Date:  2004       Impact factor: 4.107

5.  Somatostatin-induced control of cytosolic free calcium in pituitary tumour cells.

Authors:  C Petrucci; D Cervia; M Buzzi; C Biondi; P Bagnoli
Journal:  Br J Pharmacol       Date:  2000-02       Impact factor: 8.739

Review 6.  Somatostatin receptors and their interest in diagnostic pathology.

Authors:  Marco Volante; Francesca Bozzalla-Cassione; Mauro Papotti
Journal:  Endocr Pathol       Date:  2004       Impact factor: 3.943

Review 7.  Somatostatin and somatostatin receptor physiology.

Authors:  Philip Barnett
Journal:  Endocrine       Date:  2003-04       Impact factor: 3.633

8.  Somatostatin-14 influences pituitary-ovarian axis in peripubertal rats.

Authors:  Natasa Nestorović; Milica Manojlović-Stojanoski; Natasa Ristić; Milka Sekulić; Branka Sosić-Jurjević; Branko Filipović; Verica Milosević
Journal:  Histochem Cell Biol       Date:  2008-05-21       Impact factor: 4.304

Review 9.  Somatostatin and dopamine receptors as targets for medical treatment of Cushing's Syndrome.

Authors:  C de Bruin; R A Feelders; S W J Lamberts; L J Hofland
Journal:  Rev Endocr Metab Disord       Date:  2008-07-19       Impact factor: 6.514

10.  Pituitary function following peptide receptor radionuclide therapy for neuroendocrine tumours.

Authors:  Marianne S Elston; Amanda Love; Dev Kevat; Richard Carroll; Zhen Rong Siow; Sharon Pattison; Veronica Boyle; Eva Segelov; Andrew H Strickland; David Wyld; Richard Gauci; Kim Kennedy; David Ransom
Journal:  Cancer Med       Date:  2021-10-26       Impact factor: 4.452

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.